Therapeutic comparison between treatments for Vulvar Lichen Sclerosus: study protocol of a randomized prospective and controlled trial

Renata A Belotto, Maria Cristina Chavantes, João Paulo Tardivo, Roberto Euzébio Dos Santos, Raquel Civolani Marques Fernandes, Anna Carolina Ratto Tempestini Horliana, Christiane Pavani, Daniela Fátima Teixeira da Silva, Renata A Belotto, Maria Cristina Chavantes, João Paulo Tardivo, Roberto Euzébio Dos Santos, Raquel Civolani Marques Fernandes, Anna Carolina Ratto Tempestini Horliana, Christiane Pavani, Daniela Fátima Teixeira da Silva

Abstract

Background: Vulvar lichen sclerosus (VLS) is a lymphocyte-mediated disease of unknown etiology that can cause intense itching as well stenosis, hindering the evacuation and urination. It can also limit the sex life due to severe local pruritus, pain and dyspareunia (pain during sexual intercourse). The standard treatment for this disease is the use of topical corticosteroids to reduce the clinical symptoms and to try to increase disease-free intervals. Photodynamic therapy (PDT), a treatment that associates a light radiation with a photosensitizing agent and photobiomodulation (PBM) are therapies that can promote effective immunomodulatory responses at the application site by means of photophysical and photochemical phenomena from the molecular to the systemic level, which promote their use in chronic dermatoses. The aim is to compare the effects of PDT, PBM, and topical corticosteroid in VLS evaluating clinical, histological, immunohistochemical and spectroscopic responses.

Methods: The study is prospective, randomized and controlled, in a population of 60 women with histological diagnoses of VLS. There will be 3 treatments groups: PDT, PBM and topical corticosteroid (control group), where will be allocated by randomization 20 patients in each one. The clinical course will be monitored by measuring local temperature, itching, atrophy, and the area of the lesion. Histologically, the slides will be classified and will have the ordering of collagen fibers quantified. Immunohistochemical analysis will be done using the markers IFN-γ, TGF-β, CD4, CD8, IL-1, p53 and Ki-67. Finally, the spectroscopic evaluation will be done by reflectance. Descriptive and inferential statistical analyses will be conducted to compare the groups and make associations between different responses. The study is an open-label for patients with active symptomatic disease with a period of 1 year follow-up to determine the rate of recurrence in each groups.

Discussion: The immunological effects of PDT and PBM are described by several authors in inflammatory skin diseases, stimulating the production and organization of the associated collagen. Thus, it is reasonable to determine the efficacy and safety of these new treatments in VLS, in comparison to the control group, analyzing the recurrence time, the impact on the optical properties of the skin, and the benefit to patients.

Trial registration: ClinicalTrials.gov: NCT02416531 .

Keywords: Collagen; Corticosteroid; Methylene blue; Photobiomodulation; Photodynamic Therapy.

Conflict of interest statement

Ethics approval and consent to participate

The project was submitted to the Committee for Research Ethics of the Nove de Julho University, and was approved with CAAE number 34715314.6.3001.0069 issued on 08/27/2014. The trial it was registrated on Consent for publication

The patients signed the Free and Informed Consent, which contains the permission for publication of their images for academic research purposes.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Figures

Fig. 1
Fig. 1
Photo of the vulva highlighting the 8 points of irradiation for PDT and PBM

References

    1. Kreuter A, Wischnewski J, Terras S, Altmeyer P, Stucker M, Gambichler T. Coexistence of lichen sclerosus and morphea: A retrospective analysis of 472 patients with localized scleroderma from a German tertiary referral center. J Am Acad Dermatol. 2012;67(6):1157–1162. doi: 10.1016/j.jaad.2012.04.003.
    1. Oyama N, Chan I, Neill SM, Hamada T, South AP, Wessagowit V, Wojnarowska F, D'Cruz D, Hughes GJ, Black MM, et al. Autoantibodies to extracellular matrix protein 1 in lichen sclerosus. Lancet. 2003;362(9378):118–123. doi: 10.1016/S0140-6736(03)13863-9.
    1. Gambichler T, Kammann S, Tigges C, Kobus S, Skrygan M, Meier JJ, Kohler CU, Scola N, Stucker M, Bechara FG, et al. Cell cycle regulation and proliferation in lichen sclerosus. Regul Pept. 2011;167(2–3):209–214. doi: 10.1016/j.regpep.2011.02.003.
    1. Terlou A, Santegoets LAM, van der Meijden WI, Heijmans-Antonissen C, Swagemakers SMA, van der Spek PJ, Ewing PC, van Beurden M, Helmerhorst TJM, Blok LJ. An Autoimmune Phenotype in Vulvar Lichen Sclerosus and Lichen Planus: A Th1 Response and High Levels of Micro RNA-155. J Investig Dermatol. 2012;132(3):658–666. doi: 10.1038/jid.2011.369.
    1. Gambichler T, Terras S, Kreuter A, Skrygan M. Altered global methylation and hydroxymethylation status in vulvar lichen sclerosus: further support for epigenetic mechanisms. Br J Dermatol. 2014;170(3):687–693. doi: 10.1111/bjd.12702.
    1. Perez-Lopez FR, Ceausu I, Depypere H, Erel CT, Lambrinoudaki I, Rees M, Schenck-Gustafsson K, Tremollieres F, van der Schouw YT, Simoncini T. EMAS clinical guide: Vulvar lichen sclerosus in peri and postmenopausal women. Maturitas. 2013;74(3):279–282. doi: 10.1016/j.maturitas.2012.12.006.
    1. Murphy R. Lichen Sclerosus. Dermatol Clin. 2010;28(4):707–715. doi: 10.1016/j.det.2010.07.006.
    1. Selim MA, Hoang MP. A Histologic Review of Vulvar Inflammatory Dermatoses and Intraepithelial Neoplasm. Dermatol Clin. 2010;28(4):649–667. doi: 10.1016/j.det.2010.07.005.
    1. Lipkin D, Kwon Y. Therapies and Nursing Care of Women with Vulvar Dermatologic Disorders. Jognn-Journal of Obstetric Gynecologic and Neonatal. Nursing. 2014;43(2):246–252.
    1. Burrows LJ, Creasey A, Goldstein AT. The Treatment of Vulvar Lichen Sclerosus and Female Sexual Dysfunction. J Sexual Med. 2011;8(1):219–222. doi: 10.1111/j.1743-6109.2010.02077.x.
    1. Monsalvez V, Rivera R, Vanaclocha F. Lichen sclerosus. Actas Dermosifiliogr. 2010;101(1):31–38. doi: 10.1016/j.ad.2009.07.004.
    1. Brodrick B, Belkin ZR, Goldstein AT. Influence of treatments on prognosis for vulvar lichen sclerosus: facts and controversies. Clin Dermatol. 2013;31(6):780–786. doi: 10.1016/j.clindermatol.2013.05.017.
    1. Hantschmann P, Sterzer S, Jeschke U, Friese K. P 53 expression in vulvar carcinoma, vulvar intraepithelial neoplasia, squamous cell hyperplasia and lichen sclerosus. Anticancer Res. 2005;25(3A):1739–1745.
    1. Thorstensen KA, Birenbaum DL. Recognition and management of vulvar dermatologic conditions: lichen sclerosus, lichen planus, and lichen simplex chronicus. J Midwifery Womens Health. 2012;57(3):260–275. doi: 10.1111/j.1542-2011.2012.00175.x.
    1. Terras S, Gambichler T, Moritz RKC, Stucker M, Kreuter A. UV-A1 Phototherapy vs Clobetasol Propionate, 0.05%, in the Treatment of Vulvar Lichen Sclerosus A Randomized Clinical Trial. Jama Dermatol. 2014;150(6):621–627. doi: 10.1001/jamadermatol.2013.7733.
    1. Biniszkiewicz T, Olejek A, Kozak-Darmas I, Sieron A. Therapeutic effects of 5-ALA-induced photodynamic therapy in vulvar lichen sclerosus. Photodiagn Photodyn Ther. 2005;2(2):157–160. doi: 10.1016/S1572-1000(05)00062-1.
    1. Hillemanns P, Untch M, Prove F, Baumgartner R, Hillemanns M, Korell M. Photodynamic therapy of vulvar lichen sclerosus with 5-aminolevulinic acid. Obstet Gynecol. 1999;93(1):71–74.
    1. Osiecka BJ, Nockowski P, Jurczyszyn K, Ziolkowski P. Photodynamic therapy of vulvar lichen sclerosus et atrophicus in a woman with hypothyreosis - Case report. Photodiagn Photodyn Ther. 2012;9(2):186–188. doi: 10.1016/j.pdpdt.2012.02.002.
    1. Romero A, Hernandez-Nunez A, Cordoba-Guijarro S, Arias-Palomo D, Borbujo-Martinez J. Treatment of recalcitrant erosive vulvar lichen sclerosus with photodynamic therapy. J Am Acad Dermatol. 2007;57(2):S46–S47. doi: 10.1016/j.jaad.2006.04.005.
    1. Sotiriou E, Panagiotidou D, Ioannidis D. An open trial of 5-aminolevulinic acid photodynamic therapy for vulvar lichen sclerosus. Eur J Obstet Gynecol Reprod Biol. 2008;141(2):187–188. doi: 10.1016/j.ejogrb.2008.07.027.
    1. Belotto RA, RCM F, Santos RE, Assumpção B, Chavantes MC, DFT S. Photobiomodulation Is More Effective As The Current Treatment Of Vulvar Lichen Sclerosus? Lasers Surg Med. 2016;48 (Supplement):62.
    1. Olejek A, Olszak-Wasik K, Steplewska K, Horak S, Zamlynski J, Kozak-Darmas I, Gabriel A. Efficacy of PDT in vulvar LS treatment based on immunohistochemical analysis of CD3, CD4, CD8, CD57, Granzyme B and Fascin expression. Przeglad Menopauzalny. 2013;12(2):155–158.
    1. Olejek A, Steplewska K, Gabriel A, Kozak-Darmas I, Jarek A, Kellas-Sleczka S, Bydlinski F, Sieron-Stoltny K, Horak S, Chelmicki A, et al. Efficacy of Photodynamic Therapy in Vulvar Lichen Sclerosus Treatment Based on Immunohistochemical Analysis of CD34, CD44, Myelin Basic Protein, and Ki67 Antibodies. Int J Gynecol Cancer. 2010;20(5):879–887. doi: 10.1111/IGC.0b013e3181d94f05.
    1. Avci P, Gupta A, Sadasivam M, Vecchio D, Pam Z, Pam N, Hamblin MR. Low-Level Laser (Light) Therapy (LLLT) in Skin: Stimulating, Healing, Restoring. Semin Cutan Med Surg. 2013;32(1):41–52.
    1. Silva DFT, Gomes ASL, Vidal BD, Ribeiro MS. Birefringence and Second Harmonic Generation on Tendon Collagen Following Red Linearly Polarized Laser Irradiation. Ann Biomed Eng. 2013;41(4):752–762. doi: 10.1007/s10439-012-0720-3.
    1. Idre/UCLA. Institute for digital research and education from University of California. How is effect size used in power analysis? Viewed: 14 February 2017. .
    1. Ascencio M, Collinet P, Cosson M, Vinatier D, Mordon S. The place of photodynamic therapy in gynecology. Gynecol Obstet Fertil. 2007;35(11):1155–1165. doi: 10.1016/j.gyobfe.2007.07.035.
    1. Taub AF. Photodynamic therapy: Other uses. Dermatol Clin. 2007;25(1):101–109. doi: 10.1016/j.det.2006.09.007.
    1. Morton CA. How to optimise topical photodynamic therapy in dermatology. Photodiagn Photodyn Ther. 2006;3(2):112–115. doi: 10.1016/j.pdpdt.2006.05.001.
    1. Kushibiki T, Hirasawa T, Okawa S, Ishihara M. Regulation of miRNA Expression by Low-Level Laser Therapy (LLLT) and Photodynamic Therapy (PDT) Int J Mol Sci. 2013;14(7):13542–13558. doi: 10.3390/ijms140713542.
    1. Joensen J, Demmink JH, Johnson MI, Iversen VV, Lopes-Martins RAB, Bjordal JM. The Thermal Effects of Therapeutic Lasers with 810 and 904 nm Wavelengths on Human Skin. Photomed Laser Surg. 2011;29(3):145–153. doi: 10.1089/pho.2010.2793.
    1. Watson MK, Cazzini P, Mayer J, Gottdenker N, Reavill D, Parry N, Fox JG, Sakamoto K. Histology and immunohistochemistry of severe inflammatory bowel disease versus lymphoma in the ferret (Mustela putorius furo) J Vet Diagn Investig. 2016;28(3):198–206. doi: 10.1177/1040638716641156.
    1. Farrell AM, Dean D, Millard PR, Charnock FM, Wojnarowska F. Cytokine alterations in lichen sclerosus: an immunohistochemical study. Br J Dermatol. 2006;155(5):931–940. doi: 10.1111/j.1365-2133.2006.07414.x.
    1. Kauppila S, Kotila V, Sci L, Knuuti E, Vare PO, Vittaniemi P, Nissi R. The effect of topical pimecrolimus on inflammatory infiltrate in vulvar lichen sclerosus. Am J Obstet Gynecol. 2010;202(2):181e181–181e184. doi: 10.1016/j.ajog.2009.09.030.
    1. Balbino CA, Pereira LM, Curi R. Mecanismos envolvidos na cicatrização: uma revisão. Braz J Pharm Sci. 2005;41(1):27–51.
    1. Gambichler T, Belz D, Terras S, Kreuter A. Humoral and cell-mediated autoimmunity in lichen sclerosus. Br J Dermatol. 2013;169(1):183–184. doi: 10.1111/bjd.12220.
    1. Yeh NG, Wu CH, Cheng TC. Light-emitting diodes-Their potential in biomedical applications. Renew Sustain Energy Rev. 2010;14(8):2161–2166. doi: 10.1016/j.rser.2010.02.015.
    1. Hunter M, Backman V, Popescu G, Kalashnikov M, Boone CW, Wax A, Gopal V, Badizadegan K, Stoner GD, Feld MS. Tissue self-affinity and polarized light scattering in the Born approximation: A new model for precancer detection. Phys Rev Lett. 2006;97(13):138102–138106. doi: 10.1103/PhysRevLett.97.138102.
    1. Bish SF, Rajaram N, Nichols B, Tunnel JW. Development of a noncontact diffuse optical spectroscopy probe for measuring tissue optical properties. J Biomed Opt. 2011;16(12):120505.120501–120505.120503. doi: 10.1117/1.3662459.
    1. Zonios G, Dimou A. Light scattering spectroscopy of human skin in vivo. Opt Express. 2009;17(3):1256–1267. doi: 10.1364/OE.17.001256.
    1. Zhong X, Wang J, Shi R, Zhu D. Reflectance spectroscopy for evaluating optical clearing efficacy of skin in vivo In Tuchin VV, Duncan DD, Larin KV, Leahy MJ, Wang RK, eds. Bellingham: Dynamics and Fluctuations in Biomedical Photonics X. Proc. of SPIE. 2013; vol 8580: 85800P85801-85800P85806.
    1. Savenkov SN, Oberemok EA, Mamilov SA, Esman SS, Asimov MM. Characteristics of Light Scattering by Normal and Modified Areas of Skin Tissue. J Appl Spectrosc. 2011;78(1):87–94. doi: 10.1007/s10812-011-9429-6.

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren